Bcl-2 Inhibitor Venetoclax (Abt-199) And Mek Inhibitor Gdc-0973 Synergise To Target Aml Progenitors And Overcome Drug Resistance With The Use Of Pet Scanning In A Mouse Model Of Hr-Mds To Monitor Response To Treatment

Introduction: Targeted drugs are needed for HR-MDS/AML, particularly in elderly patients and Venetoclax, approved for some CLL, gives promising results in elderly AML. Assays to predict response to treatment may enable us to deliver personalized treatment. We sought to determine the most informative assay to predict response; viability assays can directly measure the effects of reagents on growth. Progenitor assays can potentially determine if the reagents can target diseased primitive cells. PET scanning can be used to follow response to treatment.